{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:34:17Z","timestamp":1789986857336,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.tjpad.2026.100477","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:46:04Z","timestamp":1768715164000},"page":"100477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A regional framework for the detection and management of ARIA with anti-amyloid therapies in early Alzheimer\u2019s disease in Asia"],"prefix":"10.1016","volume":"13","author":[{"given":"So Young","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1988-6924","authenticated-orcid":false,"given":"Ta-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Ching","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-7376","authenticated-orcid":false,"given":"Won Jin","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9244-4298","authenticated-orcid":false,"given":"Nagaendran","family":"Kandiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9913-4804","authenticated-orcid":false,"given":"Sumeet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2756-1786","authenticated-orcid":false,"given":"Young Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-4021","authenticated-orcid":false,"given":"Amitabh","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tjpad.2026.100477_bib0001","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Public Health"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100477_bib0002","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ibra.12181","article-title":"Global, regional, and national burdens of Alzheimer's disease and other forms of dementia in the elderly population from 1999 to 2019: a trend analysis based on the Global Burden of Disease Study 2019","volume":"10","author":"Su","year":"2024","journal-title":"Ibrain"},{"key":"10.1016\/j.tjpad.2026.100477_bib0003","first-page":"1","article-title":"Dementia warning for the Asia-Pacific region","volume":"14","year":"2015","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100477_bib0005","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100477_bib0006","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/ADR-220059","article-title":"Current and future trends in biomarkers for the early detection of Alzheimer's Disease in Asia: expert opinion","volume":"6","author":"Kandiah","year":"2022","journal-title":"J Alzheimers Dis Rep"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100477_bib0007","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","article-title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives","volume":"14","author":"Kim","year":"2025","journal-title":"Transl Neurodegener"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100477_bib0008","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100477_bib0009","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.tjpad.2026.100477_bib0010","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100477_bib0011","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3174\/ajnr.A8469","article-title":"Alzheimer Disease Anti-Amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities","volume":"46","author":"Cogswell","year":"2025","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100477_bib0012","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s10072-023-07194-w","article-title":"Efficacy of anti-amyloid-\u00df monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis","volume":"45","author":"Dantas","year":"2024","journal-title":"Neurol Sci"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100477_bib0013","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.3174\/ajnr.A7586","article-title":"Amyloid-related imaging abnormalities with emerging Alzheimer Disease therapeutics: detection and reporting recommendations for clinical practice","volume":"43","author":"Cogswell","year":"2022","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100477_bib0014","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100477_bib0015","doi-asserted-by":"crossref","DOI":"10.1148\/rg.230009","article-title":"Amyloid-related imaging abnormalities in Alzheimer disease treated with anti-Amyloid-\u03b2 therapy","volume":"43","author":"Agarwal","year":"2023","journal-title":"Radiographics"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100477_bib0016","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100477_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100477_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-240684","article-title":"A framework for best practices and readiness in the advent of anti-amyloid therapy for early Alzheimer's disease in Asia","volume":"101","author":"Lee","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100477_bib0019","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/ene.12546","article-title":"Association between white matter hyperintensity and medial temporal atrophy at various stages of Alzheimer's disease","volume":"22","author":"Kandiah","year":"2015","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100477_bib0020","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/joim.12495","article-title":"Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region","volume":"280","author":"Chen","year":"2016","journal-title":"J Intern Med"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100477_bib0021","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/jnnp-2016-315324","article-title":"Prevalence, risk factors and consequences of cerebral small vessel diseases: data from three Asian countries","volume":"88","author":"Hilal","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl A100","key":"10.1016\/j.tjpad.2026.100477_bib0022","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/ijs.12270","article-title":"Race-ethnicity and cerebral small vessel disease\u2013comparison between Chinese and White populations","volume":"9","author":"Mok","year":"2014","journal-title":"Int J Stroke"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100477_bib0023","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5853\/jos.2023.04287","article-title":"Prevalence of cerebral amyloid angiopathy pathology and strictly lobar microbleeds in East-Asian versus Western populations: a systematic review and meta-analysis","volume":"26","author":"De Kort","year":"2024","journal-title":"J Stroke"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100477_bib0024","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s10038-022-01050-z","article-title":"Genetics of Alzheimer's disease: an East Asian perspective","volume":"68","author":"Miyashita","year":"2023","journal-title":"J Hum Genet"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100477_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000330492","article-title":"Regional differences in effects of APOE \u025b4 on cognitive impairment in non-demented subjects","volume":"32","author":"Norberg","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100477_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000334607","article-title":"Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4\/4) among patients diagnosed with Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"38","author":"Ward","year":"2012","journal-title":"Neuroepidemiology"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100477_bib0027","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40120-024-00604-x","article-title":"Donanemab in Japanese patients with early Alzheimer's Disease: subpopulation analysis of the TRAILBLAZER-ALZ 2 randomized trial","volume":"13","author":"Sato","year":"2024","journal-title":"Neurol Ther"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100477_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100160","article-title":"Clarity AD: asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease","volume":"12","author":"Chen","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100477_bib0029","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1017\/S0266462320000628","article-title":"Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward","volume":"36","author":"Lou","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100477_bib0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with anti-amyloid Beta therapy","volume":"9","author":"Barakos","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100477_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with Donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100477_bib0032","unstructured":"Eisai Inc. Leqembi (lecanemab) [package insert] U.S. Food and Drug Administration. 2023 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269Orig1s001lbl.pdf Accessed April 2025."},{"key":"10.1016\/j.tjpad.2026.100477_bib0033","unstructured":"Eli Lilly and Company. Kisunla (donanemab) [package insert] U.S. Food and Drug Administration. 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761248s000lbl.pdf Accessed April 2025."},{"issue":"1","key":"10.1016\/j.tjpad.2026.100477_bib0034","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"7806","key":"10.1016\/j.tjpad.2026.100477_bib0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.tjpad.2026.100477_bib0036","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-a\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100477_bib0037","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100477_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70062","article-title":"Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100477_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1326784","article-title":"Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications","volume":"18","author":"Doran","year":"2024","journal-title":"Front Neurosci"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100477_bib0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3348\/jksr.2024.0147","article-title":"\uc54c\uce20\ud558\uc774\uba38\ubcd1\uc5d0\uc11c \ud56d\uc544\ubc00\ub85c\uc774\ub4dc \ub2e8\uc77c\ud074\ub860\ud56d\uccb4 \uce58\ub8cc\uc81c\uc5d0 \uc758\ud55c \uc544\ubc00\ub85c\uc774\ub4dc \uad00\ub828 \uc601\uc0c1 \uc774\uc0c1: \ud45c\uc900 \uc790\uae30\uacf5\uba85\uc601\uc0c1 \ud504\ub85c\ud1a0\ucf5c\uc5d0 \ub300\ud55c \uc804\ubb38\uac00 \uad8c\uace0\uc548 [Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: expert Recommendation for Standard MRI Protocol]","volume":"86","author":"Kim","year":"2025","journal-title":"J Korean Soc Radiol"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100477_bib0041","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3348\/kjr.2024.0105","article-title":"Amyloid-related imaging abnormalities in the era of anti-Amyloid beta monoclonal antibodies for Alzheimer's Disease: recent updates on clinical and imaging features and MRI monitoring","volume":"25","author":"Jeong","year":"2024","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.tjpad.2026.100477_bib0042","article-title":"Amyloid-related imaging abnormalities (ARIA) with emerging Alzheimer\u2019s Disease therapeutics: detection and reporting recommendations for clinical practice","year":"2023","journal-title":"Recommended Reporting Templates"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100477_bib0043","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1002\/alz.13785","article-title":"Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset","volume":"20","author":"Galvin","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100477_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100695","article-title":"The impact of real-world evidence in implementing and optimizing Alzheimer's disease care","volume":"6","author":"Hampel","year":"2025","journal-title":"Med"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100477_bib0045","article-title":"Generating real-world evidence in early Alzheimer's disease: considerations for applying the target trial emulation framework to study the safety of anti-amyloid therapies","volume":"11","author":"Li","year":"2025","journal-title":"Alzheimers Dement (N Y)"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:56:02Z","timestamp":1773975362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726000014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2274580726000014"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100477","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A regional framework for the detection and management of ARIA with anti-amyloid therapies in early Alzheimer\u2019s disease in Asia","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100477"}}